CRISPR Therapeutics AG
CRSP
$43.34
-$2.19-4.81%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -141.76% | 23.37% | -62.60% | -119.71% | 180.80% |
| Total Depreciation and Amortization | -1.18% | -3.78% | -2.34% | -4.32% | -16.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.26% | -1.10% | -16.78% | -44.64% | -40.70% |
| Change in Net Operating Assets | 88.06% | -176.78% | 113.27% | 470.33% | -545.02% |
| Cash from Operations | 47.92% | -168.25% | 28.27% | 1,147.32% | 15.23% |
| Capital Expenditure | 65.58% | 89.66% | 80.11% | 76.43% | 88.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 231.43% | -230.71% | -157.24% | -180.30% | 52.34% |
| Cash from Investing | 229.93% | -233.17% | -158.50% | -183.00% | 53.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -56.66% | 519.54% | -- | 5,561.25% | 1,471.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -56.66% | 519.54% | -102.78% | 5,561.25% | 1,471.39% |
| Foreign Exchange rate Adjustments | -242.62% | 256.25% | -92.86% | -134.38% | -46.96% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 152.40% | -411.81% | -321.91% | 140.70% | 51.61% |
